IBRX Barry J Simon sells $1.7M worth of shares
Feb 25, 2026, 5:35 AM
0.00%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
Barry J Simon sold 165,000 shares of IBRX on 23 February at $10.25 per share, worth a total of $1.7M. They now own 2,925,821 IBRX shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.